Bionexus Gene Lab Corp 2026年季度报告

Commission File Number:001-41750 BioNexus Gene Lab Corp. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer, “ “ accelerated filer, “ “non- If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ TABLE OF CONTENTS PART I – FINANCIAL INFORMATIONPageItem 1.Financial Statements4Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations31Item 3.Quantitative and Qualitative Disclosures About Market Risk40Item 4.Controls and Procedures41 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains statements that may be deemed to be “forward-looking statements” within the meaningof the federal securities laws. These statements relate to anticipated future events, future results of operations and or future financialperformance. In some cases, you can identify forward-looking statements by their use of terminology such as “anticipate,” “believe,”“could,” “estimate,” “expect,” “future,” “intend,” “may,” “ought to,” “plan,” “possible,” “potentially,” “predicts,” “project,” “should,”“will,” “would,” negatives of such terms or other similar terms. These forward-looking statements involve known and unknown risks, our goals and strategies; our future business development, results of operations and financial condition; our estimates regarding expenses, future revenues, capital requirements and our need for additional financing; our estimates regarding the market opportunity for our services; the impact of government laws and regulations; our ability to recruit and retain qualified personnel; our failure to comply with regulatory guidelines; uncertainty in industry demand; general economic conditions and market conditions in the diagnostics, specialty chemicals and contract development andmanufacturing (CDMO), and digital asset treasury strategies; future sales of large blocks or our securities, which may adversely impact our share price; anddepth of the trading market in our securities. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Forward-looking statements reflectour current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including those You should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-lookingstatements are reasonable,we cannot guarantee that future results,levels of activity,performance and events andcircumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no TOTAL STOCKHOLDERS’ EQUITY * Issued and outstanding shares of common stock have been adjusted as below:1) for the periods prior to April 7, 2025, to reflect the 1-for-10 reverse stock split effected on that date on a retroactive basis asdescribed in Note 15. See accompanying notes to the consolidated financial statements. BIONEXUS GENE LAB CORP.CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY 10 reverse stock split effected on April 7, 2025 and the 1-for-12 reverse stock split effected on July 20, 2023, on a retroactive basis. See accompanying notes to the condensed consolidated financial statements. BIONEXUS GENE LAB CORP.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND BioNexus Gene Lab Corp. (the “Company”) was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, theCompany acquired all the outstanding capital stock of Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation (“BioNexusMalaysia”). BioNexus Malaysia was incorporated in Malaysia on April 7, 2015 and subsequently changed its name to MRNA The principal office address is Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, No.5 Jalan Bangsar Utama 1, Kuala Lumpur,Malaysia, our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Mal